Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Yellow Fever Vaccination Response

Posted on by Kimberley Fox, MD, MPH, Immunizations Systems Branch Chief, Global Immunization Division
Jennie Harris
Jennie Harris, Immunizations Systems, Global Immunization Division
Kim Fox
Kim Fox, MD, MPH, Immunizations Systems Branch Chief, Global Immunization Division

In December 2015, a yellow fever outbreak started in Angola and quickly spread within the country and to its neighbor, the Democratic Republic of Congo (DRC). Laboratory testing confirmed 962 cases, but there were thousands of suspected cases, making this the largest reported outbreak in 30 years. A critical aspect to yellow fever outbreak response is vaccination campaigns in the affected areas. One dose of yellow fever vaccine is capable of providing lifelong protection. Thus the World Health Organization (WHO) keeps a stockpile of 6 million yellow fever vaccine doses for outbreak response. However, the 2016 outbreak response campaigns in Angola and DRC used almost 30 million vaccine doses, far more than had been needed in recent outbreaks.

A vaccination campaign scheduled for August 2016 targeted 8 million people in DRC’s capital city of Kinshasa. However, at that time, 8 million doses of yellow fever vaccine were not available in the global supply. Due to this vaccine shortage, WHO recommended a strategy that had worked well in a couple of small studies but had never been used during a large-scale response effort: administering 1/5 of the regular dose (also called a “fractional” dose). This meant that one standard dose of vaccine could vaccinate up to 5 people. Officials in DRC agreed to this strategy and the Kinshasa campaign administered fractional dose yellow fever vaccine to all non-pregnant adults and children age two years and over. Children under 2 years old and pregnant women received full doses because the fractional dose had never been studied in children or pregnant women. Since the target population and the campaign environment were very different from those in the controlled research settings where fractional dose vaccine had previously been used, DRC health authorities and yellow fever experts globally felt it was important to evaluate fractional dose vaccine during this campaign. Specifically, everyone wanted evidence that fractional dose vaccination caused an immune response in recipients that would be sufficient to protect them from yellow fever virus infection.

With only one month notice before the start of the campaign, the CDC and the DRC’s Institut National de Recherche Biomedicale quickly developed an evaluation plan, with USAID providing key financial support. Working at six of the more than 2000 vaccination sites in Kinshasa, the evaluation team enrolled 760 adults and children (aged >2 years) during the 10-day vaccination campaign. Participants provided blood samples before vaccination and one month after vaccination. These samples are currently being tested to see if participants developed antibodies that will protect them against yellow fever. One year after vaccination, evaluation staff will collect an additional blood sample from participants to see if the levels of antibodies are still high enough to provide protection against yellow fever. If the fractional dose is found to provide a sufficient immune response, fractional dose vaccination may be used more frequently in outbreak response campaigns. This would reduce the vaccine supply needs during outbreaks and significantly increase the global capacity to respond to large outbreaks like the recent one in Angola and DRC.

Posted on by Kimberley Fox, MD, MPH, Immunizations Systems Branch Chief, Global Immunization DivisionTags , , , , ,

One comment on “Yellow Fever Vaccination Response”

Comments listed below are posted by individuals not associated with CDC, unless otherwise stated. These comments do not represent the official views of CDC, and CDC does not guarantee that any information posted by individuals on this site is correct, and disclaims any liability for any loss or damage resulting from reliance on any such information. Read more about our comment policy ».

Post a Comment

Your email address will not be published. Required fields are marked *

All comments posted become a part of the public domain, and users are responsible for their comments. This is a moderated site and your comments will be reviewed before they are posted. Read more about our comment policy »

TOP